miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

被引:81
作者
Ji, Yun [1 ]
Wrzesinski, Claudia [2 ]
Yu, Zhiya [2 ]
Hu, Jinhui [1 ]
Gautam, Sanjivan [1 ]
Hawk, Nga V. [1 ]
Telford, William G. [1 ]
Palmer, Douglas C. [2 ]
Franco, Zulmarie [2 ]
Sukumar, Madhusudhanan [2 ]
Roychoudhuri, Rahul [2 ]
Clever, David [2 ]
Klebanoff, Christopher A. [2 ]
Surh, Charles D. [3 ]
Waldmann, Thomas A. [4 ]
Restifo, Nicholas P. [2 ]
Gattinoni, Luca [1 ]
机构
[1] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Acad Immunol & Microbiol, Inst Basic Sci, Pohang 790784, South Korea
[4] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
microRNA-155; adoptive immunotherapy; lymphodepletion; homeostatic cytokines; INCREASED INTENSITY LYMPHODEPLETION; METASTATIC MELANOMA; ADOPTIVE IMMUNOTHERAPY; IMMUNE-SYSTEM; STEM-CELLS; THERAPY; CANCER; MICRORNA-155; RESPONSES; EFFECTOR;
D O I
10.1073/pnas.1422916112
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic gamma c cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 40 条
  • [1] Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer
    Acquavella, Nicolas
    Kluger, Harriet
    Rhee, John
    Farber, Leonard
    Tara, Harold
    Ariyan, Stephan
    Narayan, Deepak
    Kelly, William
    Sznol, Mario
    [J]. JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) : 569 - 576
  • [2] CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Antony, PA
    Piccirillo, CA
    Akpinarli, A
    Finkelstein, SE
    Speiss, PJ
    Surman, DR
    Palmer, DC
    Chan, CC
    Klebanoff, CA
    Overwijk, WW
    Rosenberg, SA
    Restifo, NP
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (05) : 2591 - 2601
  • [3] MicroRNAs: Target Recognition and Regulatory Functions
    Bartel, David P.
    [J]. CELL, 2009, 136 (02) : 215 - 233
  • [4] Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
    Burns, William R.
    Zheng, Zhili
    Rosenberg, Steven A.
    Morgan, Richard A.
    [J]. BLOOD, 2009, 114 (14) : 2888 - 2899
  • [5] A Potent Vaccination Strategy That Circumvents Lymphodepletion for Effective Antitumor Adoptive T-cell Therapy
    Cho, Hyun-Il
    Reyes-Vargas, Eduardo
    Delgado, Julio C.
    Celis, Esteban
    [J]. CANCER RESEARCH, 2012, 72 (08) : 1986 - 1995
  • [6] Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
    Costinean, S
    Zanesi, N
    Pekarsky, Y
    Tili, E
    Volinia, S
    Heerema, N
    Croce, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (18) : 7024 - 7029
  • [7] Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
    Di Stasi, Antonio
    Tey, Siok-Keen
    Dotti, Gianpietro
    Fujita, Yuriko
    Kennedy-Nasser, Alana
    Martinez, Caridad
    Straathof, Karin
    Liu, Enli
    Durett, April G.
    Grilley, Bambi
    Liu, Hao
    Cruz, Conrad R.
    Savoldo, Barbara
    Gee, Adrian P.
    Schindler, John
    Krance, Robert A.
    Heslop, Helen E.
    Spencer, David M.
    Rooney, Cliona M.
    Brenner, Malcolm K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) : 1673 - 1683
  • [8] MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer
    Dudda, Jan C.
    Salaun, Bruno
    Ji, Yun
    Palmer, Douglas C.
    Monnot, Gwennaelle C.
    Merck, Estelle
    Boudousquie, Caroline
    Utzschneider, Daniel T.
    Escobar, Thelma M.
    Perret, Rachel
    Muljo, Stefan A.
    Hebeisen, Michael
    Rufer, Nathalie
    Zehn, Dietmar
    Donda, Alena
    Restifo, Nicholas P.
    Held, Werner
    Gattinoni, Luca
    Romero, Pedro
    [J]. IMMUNITY, 2013, 38 (04) : 742 - 753
  • [9] Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    Dudley, Mark E.
    Yang, James C.
    Sherry, Richard
    Hughes, Marybeth S.
    Royal, Richard
    Kammula, Udai
    Robbins, Paul F.
    Huang, JianPing
    Citrin, Deborah E.
    Leitman, Susan F.
    Wunderlich, John
    Restifo, Nicholas P.
    Thomasian, Armen
    Downey, Stephanie G.
    Smith, Franz O.
    Klapper, Jacob
    Morton, Kathleen
    Laurencot, Carolyn
    White, Donald E.
    Rosenberg, Steven A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) : 5233 - 5239
  • [10] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Dudley, ME
    Wunderlich, JR
    Yang, JC
    Sherry, RM
    Topalian, SL
    Restifo, NP
    Royal, RE
    Kammula, U
    White, DE
    Mavroukakis, SA
    Rogers, LJ
    Gracia, GJ
    Jones, SA
    Mangiameli, DP
    Pelletier, MM
    Gea-Banacloche, J
    Robinson, MR
    Berman, DM
    Filie, AC
    Abati, A
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2346 - 2357